Using advanced imaging to improve treatment for heart disease caused by amyloidosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on transthyretin amyloid cardiomyopathy (ATTR-CM), a heart condition that affects the heart muscle's function. It aims to utilize a novel imaging technique, 18F-fluoride PET, to better understand calcium deposition in the heart and how it relates to the effectiveness of the drug tafamidis. By optimizing imaging protocols, the study seeks to establish clear diagnostic thresholds and track disease progression in patients with ATTR-CM. The findings could lead to improved monitoring and treatment strategies for this condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Completion of informed consent
* Age \> 40 years for patients with ATTR or AL cardiac amyloidosis and age \>30 years for patients with HCM
* ATTR cardiac amyloid according to Expert Consensus Recommendations
* AL amyloidosis according to Expert Consensus Recommendations
* Hypertrophic cardiomyopathy according to European Society of Cardiology guidelines

Exclusion Criteria:

* Inability or unwilling to give informed consent
* Women who are pregnant, breastfeeding or of child-bearing potential (women who have experienced menarche, are pre-menopausal and have not been sterilised) will not be enrolled into the trial.
* Renal dysfunction (eGFR ≤30 mL/min/1.73m2)
* NYHA Class IV heart failure
* Patients with atrial fibrillation and poor rate control.
* Contraindications to MR
* Previous history of contrast allergy of adverse reactions (gadolinium)
* Contraindications to tafamidis therapy

Where it's running

• University Medical Centre Groningen
  Groningen, Netherlands Recruiting

Study contacts

• Principal investigator: Marc Dweck, MD PhD — Centre of Cardiovascular Science
• Study coordinator: Riemer Slart, MD PhD
• Email: r.h.j.a.slart@umcg.nl
• Phone: +31503611835

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding Atrioventricular Regurgitation in ATTR Amyloid Cardiomyopathy

  This study is trying to understand how common certain heart valve problems are in people with ATTR amyloid cardiomyopathy and create better ways to measure their severity.

  Recruiting at 8 sites Medical University of Vienna · Graz, Styria and 7 other locations · NCT06836011

• Observing the natural course of transthyretin amyloidosis

  This study is looking to see how transthyretin amyloidosis progresses over time in over 1,600 adults while also gathering information on how well treatments like eplontersen work.

  Recruiting at 73 sites AstraZeneca · La Jolla, California and 88 other locations · NCT06465810

• Acoramidis in adults with transthyretin amyloid cardiomyopathy in France

  This is an observational study to see how acoramidis is used in everyday care for adults with ATTR‑CM in France and how it affects their quality of life and daily function.

  Recruiting Bayer · Many Locations · NCT07791160

• Acoramidis for transthyretin amyloid cardiomyopathy in routine care

  See how acoramidis works for adults with transthyretin amyloid cardiomyopathy (wild-type or variant) when given as part of regular clinical care.

  Recruiting at 17 sites Bayer · Multiple Locations and 16 other locations · NCT07235462

• Coramitug (NNC6019-0001) for heart failure from transthyretin amyloid cardiomyopathy

  This study tests whether coramitug (NNC6019-0001) can lower the risk of heart-related death and illness in adults with transthyretin amyloid cardiomyopathy (ATTR-CM) while they continue their usual heart medicines.

  Recruiting at 237 sites Phase 3 Novo Nordisk A/S · Phoenix, Arizona and 298 other locations · NCT07207811

• Registry for studying Transthyretin Amyloid Cardiomyopathy in Thailand

  This study is collecting information from people with Transthyretin Amyloid Cardiomyopathy in Thailand to better understand the disease and improve early detection and treatment options.

  Recruiting Mahidol University · Bangkok and 7 other locations · NCT06338696

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.